Bone Solutions Inc. has successfully completed 250 cases with OsteoCrete® Magnesium-Based Bone Void Filler.
DALLAS, Oct. 2, 2018
DALLAS, Oct. 2, 2018 /PRNewswire/ -- Bone Solutions Inc. (BSI), an ortho-biologics technology company announces the first 250 cases of implanted OsteoCrete®. OsteoCrete® is a Magnesium-based bone void filler is designed to assist with bone repair and generation, and it's the first in the U.S. to incorporate magnesium, a critical property for bone health and development.
"In our initial launch phase, we have successfully implanted over 2200cc's of OsteoCrete® bone void filler. OsteoCrete® provides a combination of compressive strength, non-expanding features, and characteristics for optimal binding qualities. OsteoCrete® is 100% resorbable which makes it ideal for surgeons while providing enhanced patient outcomes. Many modern devices used for bone repair or replacement are calcium-based and do not exhibit the same quality or features as OsteoCrete®.
BSI will be immediately expand our clinical and commercial footprint, establishing various distribution partners throughout US. This will allow the company to build a stronger presence in the marketplace for bone graft substitutes." stated BSI president and CEO, Drew Diaz.
About Bone Solutions Inc.
Bone Solutions Inc. ('BSI') (www.bonesolutionsinc.com) is an orthobiologics company with a vision to provide orthopedic surgeons a means to improve clinical outcomes in a number of complex procedures while lowering costs. The company is revolutionizing a new solution for orthopedic surgeons for human uses with their FDA-cleared magnesium-based platform bone void filler.
Bone Solutions Inc.:
SOURCE Bone Solutions Inc.